Implantable bioelectronics startup gains funds for ‘neural dust’

Implantable bioelectronics startup gains funds for ‘neural dust’

Business news |
Iota Biosciences Inc. (Berkeley, CA) has completed $15 million in funding to help it commercialize so-called neural dust – implantable, communicating chips used to provide a platform for monitoring and treating a disease.
By Rich Pell

Share:

The company’s neural dust technology is based on implantable electronic ICs that can be powered ultrasonically and communicate using the same technology. These devices, measuring a few millimeters but expected to scale down, can record electrical information, stimulate nerves and modulate the information transmitted through nerves.

The company was founded in 2017 by Jose Carmena and Michel Maharbiz who developed the technology over many years while studying at University of California, Berkeley. They serve the company as co-CEOs.

The Series A investors include Horixons Ventures, Astellas, Bold Capital Partners, Ironfire and Shanda. The company has also named James Hattersley, a seasoned business development executive with over 25 years of business development and scientific leadership experience in the life sciences industry, as senior vice president of corporate business development.

“This funding round will advance the technology to clinical pre-trials, bringing this cutting-edge technology to the bedside as soon as possible to save lives and improve health outcomes,” said Carmena. “Iota’s neural dust platform is a major breakthrough that opens up many doors for bioelectronic medicine and brain-machine interfaces,” said Ehud Isacoff, director of UC Berkeley’s Helen Wills Neuroscience Institute.

www.iota.bio

Related articles:
Silterra pitches PMUT-on-CMOS for fingerprint sensor, medical imaging
Valencell raises funds in hearables-biosensor deal with Sonion
Wireless biosensor platform targets health-monitoring wearables

Linked Articles
Smart2.0
10s